$ cat ./records/target-malaria-conducts-first-genetically-modified-mosquito-relea-2019.txt
Target Malaria Conducts First Genetically Modified Mosquito Release in Africa in Burkina Faso
[RECORD.TXT] · cat --full
Target Malaria — funded by the Gates Foundation — conducted the first open-environment release of sterile male genetically modified Anopheles gambiae mosquitoes in sub-Saharan Africa at the village of Bana in Burkina Faso in July 2019. This Phase 1 sterile male release characterised mosquito dispersal and demonstrated that African regulatory and community engagement frameworks could support open-environment GMO insect activities — a required scientific and regulatory milestone before any gene drive release on the continent.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Funds Microneedle Patch for Needle-Free Measles-Rubella Vaccination Without Cold Chain
Next →
Gates Foundation and Johns Hopkins Host Event 201 Global Pandemic Simulation
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.